The Society for Pediatric Anesthesia recommendations for the use of opioids in children during the perioperative period by Cravero, Joseph P. et al.
Pediatric Anesthesia. 2019;29:547–571.	 	 	 | 	547wileyonlinelibrary.com/journal/pan
 
Received:	8	March	2019  |  Revised:	25	March	2019  |  Accepted:	27	March	2019
DOI: 10.1111/pan.13639  
S P E C I A L  I N T E R E S T  A R T I C L E
The Society for Pediatric Anesthesia recommendations for the 
use of opioids in children during the perioperative period
Joseph P. Cravero1  |   Rita Agarwal2  |   Charles Berde1 |   Patrick Birmingham3 |   
Charles J. Coté4 |   Jeffrey Galinkin5 |   Lisa Isaac6 |   Sabine Kost‐Byerly7 |   David Krodel3 | 










































K E Y W O R D S
monitoring,	opioids,	patient‐controlled	analgesia,	recommendations,	side	effects
548  |     CRAVERO Et Al.
1  |  INTRODUC TION







to	 perioperative	 complications.7	Unfortunately,	 few	 evidence‐based	









issues	 specific	 to	 the	 administration	 of	 opioids	 to	 children,	 such	 as	
nurse‐controlled	analgesia	(NCA),	opioid	contraindications	in	children,	
or	special	monitoring	requirements	in	this	age	group.10
The	 Society	 for	 Pediatric	 Anesthesia	 (SPA)	 initiated	 and	 sup-
ported	 the	 formulation	of	 these	 recommendations	with	 the	 intent	
of	providing	guidance	for	pediatric	anesthesiologists	that	is	(where	
possible)	 evidence‐based	 or	 a	 synthesis	 of	 expert	 opinion	 where	
evidence	is	lacking.	The	authors	did	not	attempt	to	make	this	man-
uscript	all	 encompassing,	but	 rather	were	 interested	 in	addressing	











therapy.	 This	 discussion	will	 largely	 be	 limited	 to	 pharmaceuticals	
available	 in	 North	 America;	 however,	 the	 principles	 of	 care	 apply	
broadly	 to	 any	medications	 in	 the	opioid	 class.	The	 “perioperative	
time	frame”	refers	to	administration	of	opioids	as	part	of	the	anes-
thetic	for	an	operation	and	the	recovery	period.	The	length	of	time	
will	 be	different	based	on	variations	 in	 the	 surgeries	 involved	and	
multiple	patient	factors	including	age	and	pain	sensitization.	For	the	
purposes	of	this	paper,	the	recovery	time	frame	will	be	defined	as	
the	period	 for	which	most	 surgical	patients	would	be	expected	 to	





































6  | TOPIC S AND STRENGTH OF E VIDENCE
The	 expert	 panel	was	 convened	 and	met	 in	 person	 twice	 prior	 to	
beginning	 the	process	of	 formulating	 these	 recommendations.	 The	
members	agreed	that	this	manuscript	should	focus	on	the	periopera‐
tive	time	frame	and	specifically	on	the	process	of	opioid	delivery	and	
monitoring	of	patients	 treated	with	opioids.	The	panel	 also	 agreed	















and	 the	 search	 terms	used	 is	 presented	 in	 Table	A1.	Age	 limits	 of	
0‐18	 years	were	 set	 however,	 adult	 data	were	 included	when	 the	
collected	 opinion	 of	 the	 taskforce	 determined	 that	 pediatric	 ev-



































•	 Level	 B:	 Based	 on	 prospective,	 observational	 data	 or	 appropri-










7  | AGE‐REL ATED PHARMACOKINETIC 












The	pharmacokinetics	 and	pharmacodynamics	 of	 opioid	 agents	 also	
varies	with	age.	Multiple	investigators	have	evaluated	age‐related	opi-
oid	 pharmacokinetics	 and	 pharmacodynamics	 primarily	 using	 obser-
vational	methodologies.17,18	It	is	important	to	note	that	among	these	
studies	 there	 is	 a	 poor	 correlation	 between	measured	 blood	 opioid	
concentrations	 and	 patient	 analgesia.	Many	 factors	 confound	 these	









Morphine	 is	 a	 commonly	 employed	 agent	 for	 pain	 control	 in	 new-




of	 the	 opioid.	 Glomerular	 filtration	 rate	 (GFR)	 and	 hepatic	 enzyme	
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morphine	clearance	 is	 increased	via	glucuronidation	 in	older	children	

































































TA B L E  1   (Continued)


















men	based	on	 this	model	has	been	prospectively	validated.26	 In	 this	
















opioids other than morphine






















to	 morphine	 administered	 in	 the	 PACU	 found	 that	 patients	 who	
received	methadone	perioperatively	had	lower	pain	scores	and	re-
quired	 fewer	 supplemental	medications	 in	 the	 36	 hours	 following	
their	PACU	stay.35	In	this	study	of	35	patients,	there	were	no	major	
adverse	 events.	 Another	 investigation	 evaluated	 the	 accumulated	
information	on	methadone	pharmacokinetics	in	infants	and	children	
found	no	evidence	of	maturation	of	clearance	with	age.36
Recommendation:	 Dosage	 of	 most	 synthetic	 opioids	 should	 be	
decreased	 in	 neonates	 during	 the	 first	 2‐4	 weeks	 of	 life	 (and	 for	
premature	 neonates	 until	 at	 least	 44	weeks	 post	 conceptual	 age).	









respiratory	 depressant	 effects	 in	 30	 newborns‐toddlers	 receiving	
morphine	infusions	after	cardiac	surgery.	No	age‐related	differences	
in	 respiratory	 effects	were	 observed	 at	 similar	morphine	 concen-
trations.37	 Similarly,	 in	 a	 small	 study	of	pediatric	patients	 (11	days	
to	7	years	of	age)	 receiving	morphine	after	major	surgery,	Olkkola	
et	 al	 found	 no	 difference	 in	 the	 respiratory	 depressant	 effects	 of	







a	 case	 review	of	pediatric	 patients	with	opioid‐related	 respiratory	




compared	to	older	children	and	adults	at the same blood concentra‐
tion of opioid.	The	dose	of	opioids	(dose/kg)	should	be	similar	to	older	
infants	and	children	after	6	months	of	age	 (considering	underlying	
health	 and	 previous	 exposure	 to	 opioids).	When	 beginning	 opioid	
dosing	in	infants	younger	than	3	months	of	age,	the	patient	should	
be	 in	 a	 highly	monitored	 environment	 (such	 as	 a	 step‐down	 unit,	
PACU,	or	ICU/NICU).
Strength of evidence:	B.
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•	 What	 kinds	of	 adjunctive	medications	 should	be	 added	 to	PCA	
opioid	therapy?
8.1 | Introduction—PCA vs intramuscular 
opioid delivery






tient	 satisfaction	 and	 improved	 pain	 relief,	 as	 reported	 by	 visual	
analog	scale	(VAS)	scores,	and	no	difference	in	side	effects.36	Three	
pediatric	studies	were	 identified	but	were	not	randomized	or	con-














riety	 of	 postoperative	 settings	 (abdominal,	 laparoscopic,	 thoracic,	
orthopedic	 surgery)	 and	with	 a	 variety	 of	 opioid	 choices	 (meperi-
dine,	 fentanyl,	morphine).43-56	Higher	quality	data	exist	 for	 adults.	
Meta‐analysis	 of	 randomized	 controlled	 trials	 in	 the	 adult	 perio-
perative	 population,	 performed	 for	 the	 purpose	 of	 updating	 the	
American	Society	of	Anesthesiologist's	 (ASA)	guidelines,	 found	no	
analgesic	 benefit	 of	 PCA	 over	 nurse‐administered	 IV	 opioids.57	 A	
Cochrane	review	of	49	studies	and	3412	patients	comparing	PCA	to	
intermittent	dosing	for	postoperative	pain	showed	that	patients	who	













8.3 | Opioid selection for PCA in children
The	 evidence	 is	 sparse	 and	 inconclusive	 concerning	 the	 choice	 of	
opioid	 for	 PCA	 in	 children.	 One	 randomized	 controlled	 trial	 of	
morphine	 vs	meperidine	 in	 50	 orthopedic	 patients	 8‐16	 years	 old	
showed	 no	 difference	 in	 side	 effects,	 but	 lower	 numerical	 rating	














Recommendation:	There	 is	 insufficient	 and	conflicting	evidence	




Note:	 Meperidine	 use	 for	 postoperative	 shivering	 is	 not	 ad-
dressed	in	this	recommendation.
Strength of evidence:	B.




continuous	 infusion	may	 have	many	 possible	 effects	 on	 the	 over-
all	 impact	 of	 PCA	 therapy.	Comparative	 studies	 of	 6‐12	 year	 olds	






on	 sleep	has	been	 inconsistent.	 Some	data	 indicate	an	 increase	 in	





analysis	 of	 randomized	 controlled	 trials	 (including	 both	 adult	 and	
pediatric	patients)	 indicated	that	pediatric	patients	have	an	overall	














8.5 | PCA‐by nurse or parent proxy—(Nurse‐
controlled analgesia and parent‐controlled analgesia)
Many	pediatric	patients	are	either	developmentally	or	physically	
unable	 to	 activate	 their	 PCA	 pump	 and	 require	 assistance	 from	
a	 caregiver.	 When	 control	 of	 the	 bolus	 dose	 delivery	 is	 turned	
over	to	a	caregiver,	the	technique	is	referred	to	as	PCA	by	proxy	
(PCA‐P)	 or	NCA.	One	 retrospective	 study	 of	 302	 children	man-
aged	 with	 NCA	 vs	 intermittent	 IV	 dosing	 documented	 similar	
numbers	of	adverse	events	 in	both	cohorts.	This	study	was	con-
founded	by	 the	 fact	 that	 the	NCA	cohort	 tended	 to	be	younger	
and	had	more	medical	co‐morbidities.74	A	prospective	1‐year	ob-
servational	study	of	212	children	undergoing	nurse	or	parent‐con-
trolled	 analgesia	 showed	 these	methods	were	 effective	 for	 pain	
control.	Notably,	 all	 participants	 underwent	 extensive	 standard-
ized	training	in	the	use	of	PCA‐P.	Minor	adverse	events	occurred	
in	4%	of	patients.75	A	 large	 retrospective	 review	of	10	079	chil-
dren	(average	age	4	years)	and	including	510	neonates,	revealed	39	
serious	 adverse	events	 that	 required	 resuscitation	and	naloxone	









than	 those	 on	 continuous	 infusion	 (84%	 less	 morphine	 equiva-
lents).	There	was	no	difference	in	occurrence	of	adverse	events	or	
in	subsequent	methadone	use.78	One	randomized	controlled	trial	












Recommendation:	 There	 is	 evidence	 that	NCA	 and	 parent‐con-
trolled	 analgesia	 is	 associated	 with	 safety	 and	 efficacy	 outcomes	






There	 is	 supportive	 evidence	 for	 the	 opioid	 sparing	 effect	 of	 ke-








to	 children	who	 received	 only	morphine	 similarly	 found	 an	 opioid	
sparing	 effect	 of	 ketorolac	without	 a	 difference	 in	 side	 effects.87 
A	randomized	controlled	trial	of	35	adolescents	after	spinal	fusion	
found	 lower	 postoperative	 pain	 scores	 and	 decreased	 morphine	
consumption	delivered	by	PCA	when	ketorolac	was	included	in	their	




Most	 evidence	 available	 for	 nonsterioidal	 anti‐inflammatory	 drug	
(NSAID)	effect	on	PCA	dosing	involves	ketorolac,	however	there	is	




There	 is	 supportive	 evidence	 for	 an	 opioid	 sparing	 effect	 when	
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after	 ureteroneocystostomy,	 compared	 fentanyl	 with	 intravenous	
acetaminophen	 PCA	 to	 fentanyl‐only	 PCA	 found	 that	 pain	 scores	
were	 similar	 between	 the	 groups.	However,	 a	 fentanyl	 sparing	 ef-
fect	 (53%	 reduction)	 was	 observed	 along	 with	 a	 lower	 incidence	
of	 vomiting	 and	 sedation	 in	 the	 fentanyl‐acetaminophen	 group.90 
In	another	study	of	36	children	and	adolescents	after	spinal	fusion	









9  | RECOMMENDATIONS FOR 






















use	 of	 an	 informational	 brochure	 has	 been	 shown	 to	 significantly	
improve	 the	 percentage	 of	 patients	who	 disposed	 of	 unused	 opi-
oid	 pain	 medications	 after	 surgery.99	 For	 children,	 websites	 such	
as	kidshealth.org,	provide	simple,	easy	to	read	answers	to	the	most	
common	questions	parents	have	about	opioids	for	pain	treatment.	
Additional	 links	 are	 included	 to	 provide	 additional	 information	
as	 needed.	 More	 recently	 websites,	 such	 as	 mychi	ldisi	npain.org.
uk,	 combine	 excellent	 graphics	 with	 informative	 text	 and	 video	






to	manage	 their	 child's	postoperative	pain.	Parents	 should	 receive	




9.2 | Specific opioid therapy for outpatients
There	 is	 a	 paucity	 of	 pediatric	 literature	 upon	which	 to	 formulate	














ing	 that	 it	 is	 a	 safer	 alternative	 to	 opioids.7	 The	FDA	has	 issued	
a	warning	concerning	the	use	of	tramadol	that	advises	restricted	
use	in	children	younger	than	18	years	after	tonsillectomy,	children	
younger	 than	12	years	of	 age,	 and	 adolescents	between	12	 and	
18	years	who	are	obese,	have	obstructive	sleep	apnea	 (OSA),	or	
lung	disease.105,106
Recommendation:	 Codeine	 should	 be	 avoided	 in	 children	 and	













who	 received	 ATC	 acetaminophen	 with	 hydrocodone	 were	 com-
pared	to	those	who	received	the	same	medications	“as	needed”	for	








Recommendation:	 There	 is	 insufficient	 evidence	 to	 recommend	
PRN	vs	scheduled	dosing	strategies	for	opioids	after	surgery	in	chil-
dren.	Expert	 consensus	 is	 to	use	a	PRN	strategy	until	 further	evi-
dence	is	available.
Strength of evidence:	C.
9.4 | Combinations of opioids and benzodiazepines
A	recent	FDA	review	determined	that	the	use	of	opioid	medications	







ond	 study	 found	 that	 between	2004	 and	2011	 the	 rate	 of	 opioid	
overdose	 deaths,	 in	 which	 benzodiazepines	 were	 also	 implicated,	
increased	 from	18%	 to	31%.111	However,	no	 similar	pediatric	data	
have	been	reported.
Recommendation:	 Opioid	 pain	 medications	 should	 not	 be	 pre-
scribed	with	benzodiazepines	except	in	children	for	whom	there	is	a	
specific	indication	and	alternative	treatment	options	are	inadequate.	





Several	 federal	 agencies	 and	 physician	 organizations	 (Centers	
for	Disease	Control	 [CDC],	 Substance	Abuse	 and	Mental	Health	
Services	Administration	[SAMHSA],	American	Medical	Association	
[AMA])	 have	weighed	 in	 on	 the	 over	 prescription	 of	 opioids	 for	
postoperative	 patients.	 These	 organizations	 highlight	 the	 grow-
ing	incidence	of	opioid	overdose	in	pediatric	patients,	particularly	
teenagers.	 The	 most	 common	 source	 of	 prescription	 opioids	 is	
drug	 supplies	 from	 leftover	 prescriptions	 (family,	 friends,	 neigh-
bors,	 etc)	 where	 opioid	 prescriptions	 were	 overly	 generous	 in	
order	to	avoid	any	possible	requirement	for	refilling	prescriptions.	
Recent	 studies	 have	 found	 children	 are	 prescribed	 amounts	 of	
opioids	that	significantly	exceed	the	total	administered	at	home.	








10  | OPIOID TRE ATMENT OF THE PATIENT 





•	 How	 do	 we	 approach	 analgesia	 for	 patients	 with	 central	
sensitization?
Many	 pediatric	 patients	 present	 for	 surgery	 with	 a	 history	 of	
chronic	 pain,	 be	 it	 pain	 related	 to	 “central	 sensitization”,113 
cancer	 pain,114	 chronic	 orthopedic	 conditions	 or	 other	 medi-
cal	 issues.115	Some	of	these	children	will	be	opioid	dependent	
or	 tolerant	 due	 to	 their	 treatment	with	 these	medications	 on	
a	long‐term	basis.	Furthermore,	pediatric	patients	with	chronic	
pain	who	are	on	 long	acting	or	partial	 agonist	opioid	 therapy,	
including	 methadone	 or	 buprenorphine,	 require	 special	 con-
sideration.116	There	is	little	evidence	to	guide	the	treatment	of	


















10.1 | Perioperative care of patients with chronic 




ing	 that	pediatric	patients	previously	placed	on	opioid	 infusions	 in	
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not	 available,	 but	 requirements	 to	meet	 postsurgical	 analgesic	 re-
quirements	are	affected	by	receptor	down‐regulation	and	may	need	
to	be	 increased	three	to	10	times	of	 that	 required	by	opioid	naïve	
patients.121,122	Continuous	opioid	infusion	or	patient‐controlled	an-
algesia	(PCA)	techniques	are	useful	options	in	this	subgroup.
While	 these	 recommendations	will	 not	 review	 adjunctive	 pain	
medication	use	in	detail,	 it	 is	 important	to	note	that	multiple	stud-
ies	in	children	support	adjunctive	therapies	such	as	nonopioid	pain	
relievers	 (acetaminophen,	 nonsteroidal	 ant	 inflammatory	 agents,	
gabapentin,	 tricyclic	 antidepressants),	 and/or	 regional	 anesthesia	
techniques	to	improve	pain	control	for	chronic	pain	patients	under-
going	surgery.117	In	pediatric	patients	the	use	of	multimodal	analge-
sic	 treatment	 results	 in	 decreased	 episodes	 of	 substantial	 pain.123 
In	addition,	nonpharmacological	interventions	such	as	acupuncture	
and	massage	 therapy	have	been	 shown	 to	be	 effective	 in	 amelio-
rating	pain	after	surgery	and	decreasing	chronic	pain	symptoms	 in	



































10.2 | Patients with central sensitization
Perioperative	pain	management	 for	pediatric	patients	with	central	
sensitization	 is	 largely	based	on	 consensus.	 In	 the	pediatric	popu-
lation	 the	cohort	 is	 largely	made	up	of	patients	with	 fibromyalgia,	
former	premature	newborns	with	extensive	procedure	history	from	
the	 intensive	 care	 nursery,	 those	 with	 cancer,	 and	 those	 with	 an	






patients	 on	 chronic	 opioids	 (use	 nonopioid	 analgesic	 techniques	











Pediatric	 anesthesiologists	 are	 routinely	 asked	 to	 assist	 in	 periop-
erative	pain	management,	and	there	 is	wide	agreement	that	ap-
propriate	assessment	of	pain	is	necessary	in	order	to	better	guide	
care	 during	 the	 perioperative	 and	 postoperative	 period.2,130‐132 
Unfortunately,	 there	 are	 insufficient	 data	 to	 support	 the	 bene-
ficial	effect	of	 routine	pain	assessment	on	patient	outcomes.133 
Furthermore,	 observational	 data	 evaluating	 institutional	 prac-
tices	 demonstrate	 inconsistencies	 in	 the	 frequency	 and	 nature	
of	pain	assessment	in	many	hospital	settings.134-137	Inappropriate	
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Recommendation:	 Regular	 pain	 assessments	 should	 be	 part	 of	 the	
perioperative	care/treatment	of	pediatric	patients	who	are	receiving	

























Several	 observational	 studies	 have	 reported	 average	 self‐re-
ported	 numeric	 or	 faces	 pain	 intensity	 scores	 children	 associate	





fore	be	 interpreted	 in	context.	For	 instance,	 studies	 that	based	 ti-
tration	of	opioid	doses	on	specific	pain	scores	 (most	commonly	 to	
achieve	a	 score	of	 less	 than	 four	out	of	 ten)	have	 resulted	 in	high	
rates	 of	 excessive	 sedation.150	 Other,	 more	 global	 comfort	 and	
function	outcomes	(ability	to	take	a	deep	breath	and	cough,	get	out	
of	 bed,	 etc),	 are	more	 nebulous	 but	 better	 indicators	 of	 analgesic	
need	compared	to	arbitrary	target	pain	scores.
Recommendation:	Pain	intensity	scores	can	be	used	to	assess	
a	 child's	 perceived	 degree	 of	 discomfort.	 However,	 decisions	 to	
administer	analgesics	should	take	into	consideration	patient	func-
tional	 behaviors,	 situational	 factors	 such	 as	 pain	 source,	 self‐re-
ported	 pain	 scores,	 parental	 observation,	 and	 other	 potential	




Behavioral	 observation	 instruments	 can	 be	 reliably	 used	 to	 docu-
ment	 pain	 behaviors	 in	 children	who	 cannot	 self‐report,	 including	
those	younger	than	4	years	of	age,	 infants,	neonates,	and	children	
or	 adolescents	 with	 moderate	 to	 severe	 cognitive	 impairments.	
Observational	 studies	 have	 demonstrated	 behavioral	 observation	
instruments	 can	 be	 used	 reliably	 between	 providers	 to	 document	
pain	behaviors.149,151,152	These	measures	include	(but	are	not	limited	
to):
•	 Behavior	 and	 posture‐related	 scales	 (Faces,	 Legs,	 Activity,	 Cry,	
Consolability	 [FLACC],	 Children's	 Hospital	 of	 Eastern	 Ontario	
Pain	Scale	[CHEOPS])




assessing	 pain	 in	 children	 who	 cannot	 self‐report.	 Observed	 pain	
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scores	are	sensitive	in	detecting	pain	relief	after	analgesic	adminis-
tration	and	over	time	(ie	scores	decrease	significantly	after	admin-
istration).154-160	 Observational	 studies	 have	 also	 reported	 “Mean	



























that	 other	 potential	 sources	 of	 physiologic	 distress	 (eg,	 emotional	
distress,	 hypovolemia,	 fever,	 hypercarbia)	 be	 considered	 and/or	
ruled	out	when	making	treatment	decisions.
Strength of evidence:	B.













Recommendation:	 A	 child's	 functional	 recovery	 should	 be	 as-
sessed	to	inform	treatment	plans.
Strength of evidence:	C.
11.6 | Nature and location of pain
Observational	 studies	 have	 demonstrated	 children	 as	 young	 as	
4	years	can	reliably	identify	a	pain	location	(ie	body	map)	that	is	con-
sistent	with	clinical	 findings.166,167	Additionally,	observational	data	
suggest	 that	 children	as	young	as	8	years	of	 age	can	describe	 the	
quality	and	nature	of	pain	using	word	lists	and	scales.168





12  | MONITORING OF PATIENTS ON 







erative	 time	period	monitoring	 (through	 technology	and	human	
observation)	should	include	vital	signs	and	level	of	sedation	to	as-
sess	adverse	effects	of	opioids.	The	ASA,	the	Anesthesia	Patient	
Safety	 Foundation	 (APSF),	 the	 Joint	 Commission,	 Centers	 for	




There	 are	no	prospective	 randomized	 trials	 investigating	 the	mini-
mum	monitoring	requirements	concerning	pediatric	patients	on	PCA	
opioid	 infusions.	Additionally,	 there	are	no	clinical	 trials	correlating	
levels	of	monitoring	with	 significant	 adverse	outcomes.	 In	 spite	of	
this,	a	national	survey	of	members	of	SPA,	representing	252	institu-








clude	 respiratory	 rate	 (by	 plethysmography	 or	 direct	 observation),	
and	continuous	pulse	oximetry.	Although	it	is	a	sensitive	measure	of	
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hypoventilation,	capnography	 is	not	 routinely	 recommended,	how-








New	 technologies,	 such	 as	 respiratory	 volume	 monitoring,182 
and	detection	of	 expired	 gas	moisture	or	 temperature,	 have	been	
described,	but	have	not	been	tested	or	validated	in	children	for	mon-
itoring	opioid	effects.
Although	 there	 are	 no	 studies	 to	 specifically	 differentiate	 the	
monitoring	 requirements	 for	 populations	 that	 are	 logically	 at	 in-
creased	risk	for	opioid	associated	respiratory	depression,	additional	
vigilance	is	recommended	in	such	patients.	These	populations	include:
1.	 Neonates	 (because	 of	 immaturity	 of	 respiratory	 control	 mech-
anisms	 as	 well	 as	 drug	 metabolism	 and	 clearance)
2.	 Patients	with	cerebral	palsy	(poor	coordination	of	airway	muscu-
lature,	increased	secretions)











8.	 Opioid	 naïve	 patients	 (particularly	 on	 the	 first	 postoperative	
night)




Meta‐analysis	of	adult	 studies	has	shown	the	 risk	of	 respiratory	de-
pression	 to	 be	 similar	 between	 "as	 needed"	 bolus	 administration	 of	
opioid	and	PCA	bolus	administration.184
Recommendation:	 Physiologic	monitoring	 of	 children	 receiving	
initial	 intravenous	 opioid	 treatment	 should	 include	 pulse	 oxime-
try	 for	 the	 first	24	hours	unless	 the	patient	 is	 awake	and	actively	
being	 observed.	 Continuous	 monitoring	 of	 respiratory	 rate	 and	
electrocardiogram	 should	 be	 considered	 in	 pediatric	 patients	who	
are	on	oxygen,	or	who	have	risk	factors	for	respiratory	depression.	






direct	 observation	 and	 recorded	 in	 the	medical	 record.	 Increased	
frequency	 and	 intensity	 of	 these	 observations	 is	 recommended	
for	 children	 in	 high‐risk	 groups	 in	 addition	 to	 standard	 electronic	
monitoring.
Strength of evidence:	C.
12.2 | Monitoring patients with obstructive 
sleep apnea
Of	all	the	populations	outlined	above,	the	most	commonly	encoun-
tered	 and	well	 studied	 is	 the	 growing	 cohort	 of	 pediatric	 patients	
with	sleep	apnea.	Brown	et	al185	prospectively	studied	the	effects	
of	 pediatric	 recurrent	 desaturation	 events	 on	 sensitivity	 to	 the	
respiratory	depressant	effects	of	morphine	in	20	children	with	ob-
structive	 sleep	 apnea.	Having	previously	 determined	 an	 increased	
risk	 in	 those	with	a	nighttime	oxygen	saturation	nadir	of	<85%,106 








tive	 respiratory	 depression	 is	 also	 seen	 in	 adults	with	 obstructive	
sleep	apnea.187
Obesity	 is	 strongly	 associated	 with	 obstructive	 sleep	 apnea.	
Sleep	 apnea	 is	 also	 more	 common	 in	 certain	 pediatric	 popula-
tions	 including	 African	 Americans,	 Hispanic	 Americans,	 prema-
ture	 babies,	 toddlers	who	 attend	 daycare,	 and	 children	 of	 lower	
socioeconomic	 status.186	 Of	 these,	 African	 American	 and	 syn-
dromic	 patients	 had	 the	 greatest	 risk	with	 one	 study	 document-
ing	an	incidence	12.5	and	11	times	that	of	the	baseline	Caucasian	
population.188,189






Recommendation:	 Patients	 with	 obstructive	 sleep	 apnea,	 obe-
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12.3 | Monitoring level of sedation
Excessive	sedation	has	been	found	to	predict/precede	opioid‐related	
respiratory	 depression	 and	 was	 observed	 prior	 to	 opioid‐related	
death/neurological	 injury	 in	 a	 majority	 of	 children.182	 Therefore,	
patients	receiving	PCA	or	PCA‐P,	with	or	without	a	basal	 infusion,	
should	 be	 monitored	 for	 their	 level	 of	 sedation.	 Sedation	 scales	
developed	and	validated	for	use	in	children	undergoing	procedural	
sedation,	 such	as	 the	Ramsey	Scale	or	 the	University	of	Michigan	




respiratory	 rate,	 depth,	 and	 pattern.	 Common	 sense	 requires	 res-
piratory	 evaluation	 in	 patients	 receiving	 opioid	 analgesia	 be	 done	
before	stimulating	the	patient	since	measures	after	patient	stimula-
tion	are	inaccurate.	The	POSS	grades	the	“drowsiness”	of	a	patient	




















12.4 | Institutional surveillance/safety review for 
opioid‐related adverse events
Surveillance	 for	 opioid‐related	 adverse	 events	 has	 been	 recom-
mended	 including	 regular	 review	 of	 rapid	 response	 team	 and/
or	 code	 team	 calls	 and	 the	 need	 for	 naloxone	 administration.	
Publications	of	 institutional	 review	procedures	of	 this	 nature	pro-
vide	information	regarding	risk	for	adverse	events	in	both	adults	and	
children.174,194,195	 Sophisticated	 filtering	 of	 physiologic	monitoring	
data	has	been	reported	to	detect	prevalence	of	desaturation	events	
in	patients	receiving	opioids.196	Importantly,	concerns	have	recently	
been	 raised	about	 the	 contribution	of	 “alarm	 fatigue”	 to	 failure	 to	
rescue	with	respect	to	opioid	overdose.197









Opioid‐induced	 pruritus	 is	 a	 common	 problem,	 with	 reported	 in-




of	 treatment	 of	 opioid‐induced	 pruritus	 have	 been	 limited,	 par-




review	of	10	adult	 studies	 found	overall	benefit	of	nalbuphine	 for	
treatment	of	opioid‐induced	pruritus.199
Naloxone	 has	 a	 mixed	 track	 record	 in	 pediatric	 perioperative	
care.	West	et	al	found	no	effect	on	itch	in	a	randomized	controlled	
pediatric	 trial	 of	 naloxone/morphine	 admixture	 in	PCA.200	On	 the	



















of	 perioperative	 nausea	 and	 vomiting.	Most	 of	 these	 have	 been	
studies	in	surgical	populations	with	a	high	incidence	of	nausea	and	
vomiting	such	as	tonsillectomy	and	adenoidectomy	or	strabismus	










opioid	 use	 in	 children.205-208	 Conversely,	 in	 a	 prospective,	 rand-
omized	 controlled	 trial	 of	 children	 given	 a	 propofol‐based	 anes-
thetic	 and	 dexamethasone	 for	 nausea	 and	 vomiting	 prophylaxis,	
Keidan	et	al	compared	ketorolac	to	fentanyl209	and	found	no	ap-
preciable	difference	in	postoperative	nausea	and	vomiting	in	chil-


















operative	 PCA	 found	 less	 nausea	 with	 0.25	 mcg/kg/h	 naloxone	
infusion	when	compared	to	placebo.	A	dose	finding	study	involving	
59	pediatric	patients	found	that	infusion	rates	greater	than	or	equal	

















































set	of	 recommendations	 for	practice	 involving	specific	 situations	
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